PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December: Guggenheim’s 2nd Annual Healthcare Innovation Conference: Webcasted fireside chat at 10:30 a.m. ET on Tuesday, November 11, 20 ...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim 2nd Annual Healthcare Innovation Conference (November 10-12, 20 ...

BOCA RATON, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the Southwest IDEAS Investor Conference being held November 19-20, 2025 in Dallas. Camilo Ramirez, Senior Vice President, Finance and Investor Relations, will present and host investor meetings on November 20, 2025. About red violet®At red violet, we build proprietary technologies and apply analytical capabilities to deliver iden ...

AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the succes ...

New cloud capabilities cut time to create Tables, Figures, and Listings by 50%RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific ...

KIRKLAND, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its participation in the American Heart Association (AHA) Scientific Sessions 2025, to be held November 7–10 in New Orleans. Kestra’s participation will include a late-breaking science presentation titled Primary Results from the Post-Approval Study of a Next Generation Wearable Cardioverter Defibrillator System (ACE-PAS Trial), schedu ...

DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or “the Company”), a leading distributor and manufacturer of specialty agriculture products for controlled-environment agriculture (CEA), commercial cultivation, and retail garden centers, today announced that the Company will exhibit at CannaFest Prague 2025, taking place November 7-9 2025 at PVA Expo Praha Letňany in Prague, Czech Republic. Exhibition details are included below: CannaFest Prague 2025 Date: November 7- ...

临床试验启动 - 公司宣布首例患者已在评估VOQUEZNA治疗成人嗜酸粒细胞性食管炎的2期pHalcon-EoE-201临床试验中完成给药 [1] - 该研究是首个针对EoE的大型、对照良好的酸分泌治疗临床试验 [6] - 预计将在2027年获得顶线主要和次要结果数据 [3] 试验设计与细节 - pHalcon-EoE-201是一项分为两部分的随机、双盲、安慰剂对照研究 [2] - 研究第一部分将招募80名经内镜确诊为EoE并伴有吞咽困难的成人患者，平均分配至每日一次VOQUEZNA 20 mg组或安慰剂组，治疗12周 [2] - 完成初始12周治疗期的患者有资格进入第二部分，即12周延长阶段，所有受试者将接受VOQUEZNA 20 mg治疗 [2] - 试验将在美国约40个中心进行 [4] 疾病背景与市场机会 - 嗜酸粒细胞性食管炎是一种慢性的、免疫介导的食管疾病，嗜酸性粒细胞在食管内壁积聚，导致炎症和吞咽困难等症状 [5] - 尽管对EoE的认识有所进步，但治疗选择仍然有限，目前仅有两种获批疗法 [2] - 质子泵抑制剂传统上被用作EoE的一线治疗，但均未获得FDA批准用于此适应症，且支持数据主要来自非对照研究 [2] 公司战略与产品定位 - 此次试验启动反映了公司致力于推进胃肠道疾病患者护理以及扩展VOQUEZNA临床潜力的开发战略 [2] - 该试验代表了一个解决EoE治疗领域显著未满足需求的重要机会，并可能生成数据以支持关于儿科项目的讨论，从而有望延长VOQUEZNA的监管独占期并加强长期增长战略 [2] - VOQUEZNA的酸抑制特性可能为EoE患者提供一种口服、非类固醇的治疗方法 [2] 产品信息 - VOQUEZNA是一种钾竞争性酸阻滞剂，目前已在美国获批用于治疗成人糜烂性食管炎、与糜烂性GERD相关的烧心缓解、与非糜烂性GERD相关的烧心缓解，以及与抗生素联用治疗幽门螺杆菌感染 [29] - 公司从武田制药获得了vonoprazan在美国、欧洲和加拿大的授权许可，武田在日本以及亚洲和拉丁美洲的许多国家销售该产品 [29]

Business Wins and Strategic Initiatives Drove Revenue Growth While Demand Remained Stable Higher Revenue Resulted in Gross Margin Improvement MARLBOROUGH, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2025. Three Months Ended September 30, Nine Months Ended September 30, (In millions, except per share data and percentages) 2025 2024 Change <td style="border-bottom: solid black 1pt ; pa ...

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024(Unaudited, in thousands, except ASP data) Revenue $17,244 <td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ; vertical-align: ...